ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00309959 |
|
Recruitment Status :
Completed
First Posted : April 3, 2006
Results First Posted : January 8, 2019
Last Update Posted : January 8, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Cervical Small Cell Carcinoma Cervical Squamous Cell Carcinoma Recurrent Cervical Carcinoma | Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation Other: Laboratory Biomarker Analysis | Phase 2 |
OBJECTIVES:
I. Estimate the antitumor activity of ABI-007 in patients with persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix who have failed on higher-priority treatment protocols.
II. Determine the nature and degree of toxicity of ABI-007 in this cohort of patients.
III. To determine the expression of the SPARC (secreted protein, acidic and rich in cysteine) protein in the tumor tissue and plasma (exploratory study) of patients treated with this regimen.
OUTLINE: This is an open-label, multicenter study.
Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Blood samples are collected at baseline and periodically during study for SPARC protein expression analysis by ELISA. Archived tumor tissue samples are also analyzed.
After completion of study treatment, patients are followed periodically for up to 5 years.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 37 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix |
| Study Start Date : | November 2006 |
| Actual Primary Completion Date : | February 2011 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Treatment (paclitaxel albumin-stabilized nanoparticle)
Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
|
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Given IV
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies |
- Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 [ Time Frame: CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; then every 3 months x 2; then every 6 months until disease progression for up to 5 years. ]RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above. Complete and partial responses are included in the objective tumor response rate.
- Frequency and Severity of Observed Adverse Effects Assessed by Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: Up to 5 yearsAssessed every cycle while on treatment, 30 days after the last cycle of treatment, and up to 5 years in follow-up ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix with documented disease progression
- Histologic confirmation of the original primary tumor
-
Measurable disease, defined as at least one target lesion that can be accurately measured in at least one dimension ≥ 20 mm when measured by conventional techniques, including palpation, plain x-ray, CT scan, or MRI, or ≥ 10 mm when measured by spiral CT scan
- Tumors within a previously irradiated field will be designated as nontarget lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days after completion of radiotherapy
-
Must have received 1 prior systemic chemotherapeutic regimen for management of advanced, metastatic, or recurrent squamous or nonsquamous cell carcinoma of the cervix
- Chemotherapy administered as a radiosensitizer is not a systemic chemotherapy regimen
- Not eligible for a higher priority GOG protocol
- GOG performance status 0, 1, or 2
- No active infection requiring antibiotics
- Platelet count ≥ 100,000/mm^3
- Absolute neutrophil count ≥ 1,500/mm^3
- Creatinine ≤ 1.5 times upper limit of normal (ULN)
- Bilirubin ≤ 1.5 times ULN
- SGOT and alkaline phosphatase ≤ 2.5 times ULN
- No neuropathy (sensory and motor) > grade 1
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No evidence of any other invasive malignancies within the past 3-5 years, except localized breast cancer, head and neck cancer, cervical cancer, or nonmelanoma skin cancer
- No pre-existing hearing loss/tinnitus > grade 1
- No concurrent amifostine or other protective agents
- Recovered from effects of prior surgery, radiotherapy, or chemotherapy
-
Hormonal therapy directed at malignant tumor must be discontinued at least 1 week prior to study entry
- Continuation of hormone replacement therapy permitted
- At least 3 weeks since prior biological therapy and immunotherapy
-
No more than 1 prior cytotoxic chemotherapy regimen (either with single or combination cytotoxic drug therapy)
- May have received 1 additional noncytotoxic (biologic or cytostatic) regimen, including monoclonal antibodies, cytokines, or small-molecule inhibitors of signal transduction
-
No prior radiotherapy to any portion of the abdominal cavity or pelvis
- Radiotherapy for the treatment of cervical cancer within the past 5 years allowed
- Radiotherapy for localized breast cancer, head and neck or skin allowed provided completion > 3 years prior to study entry and remains free of recurrent or metastatic disease
-
No prior chemotherapy for any abdominal or pelvic tumor
- Chemotherapy for the treatment of cervical cancer within the past 5 years allowed
- Prior adjuvant chemotherapy for localized breast cancer provided completion > 3 years prior to study entry and remains free of recurrent or metastatic disease
- No prior therapy with ABI-007 or any other taxane
- No prior anticancer treatment that would preclude study therapy
- No concurrent ritonavir, saquinavir, indinavir, nelfinavir, or anticonvulsants
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00309959
Show 26 study locations
| Principal Investigator: | David Alberts | Gynecologic Oncology Group |
| Responsible Party: | Gynecologic Oncology Group |
| ClinicalTrials.gov Identifier: | NCT00309959 |
| Other Study ID Numbers: |
GOG-0127V NCI-2009-00576 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) GOG-0127V CDR0000463520 GOG-0127V ( Other Identifier: Gynecologic Oncology Group ) GOG-0127V ( Other Identifier: CTEP ) U10CA027469 ( U.S. NIH Grant/Contract ) |
| First Posted: | April 3, 2006 Key Record Dates |
| Results First Posted: | January 8, 2019 |
| Last Update Posted: | January 8, 2019 |
| Last Verified: | December 2014 |
|
Carcinoma Carcinoma, Small Cell Small Cell Lung Carcinoma Carcinoma, Adenosquamous Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms |
Neoplasms by Site Lung Diseases Respiratory Tract Diseases Neoplasms, Complex and Mixed Paclitaxel Albumin-Bound Paclitaxel Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |